neuroblastoma
Case Study Suggests Use of Targeted Therapy, Surveillance for Germline ALK-Mutant Neuroblastoma
Premium
Two family members with a germline ALK-mutant neuroblastoma both experienced complete response to ALK inhibitors in a case study.
Stanford Medicine Laboratory for Cell and Gene Medicine Awarded Grant for CAR T-Cell Platform
The lab will use the G-Rex platform to manufacture a CAR T-cell therapy for a Phase I clinical trial.
Cancer Cell Therapies at ASGCT24
At the meeting, companies and academic centers presented early and long-term follow-up data on investigational cell therapies in several tumor types.
UK, Australian Researchers ID Tumor-Agnostic Microbiome Signature to Predict Opdivo-Yervoy Response
Premium
Researchers uncovered 22 bacteria that could predict which patients do and do not respond to combination checkpoint inhibitors across diverse cancer types.
Repare Therapeutics Begins Phase I Study of PLK4 Inhibitor in TRIM37-High Solid Cancers
The firm is evaluating RP-1664 as a potential treatment for advanced solid tumors with TRIM37 gains, amplifications, or other genetic alterations.
Oct 8, 2021